

# Use of imaging systems for patient modeling - PET and SPECT


Sasa Mutic  
Department of Radiation Oncology  
Siteman Cancer Center  
Mallinckrodt Institute of Radiology  
Washington University School of Medicine  
St. Louis, Missouri 63110

# Nuclear Medicine Imaging in RT

- **The goal is to accurately delineate and biologically characterize an individual tumor, select an appropriate course of therapy, and to predict the response at the earliest possible time**
- **Image information can be categorized as:**
  - **Anatomical**
  - **Biological**
    - » **Metabolic**
    - » **Functional**
    - » **Physiological**
    - » **Genotypic**
    - » **Phenotypic**

# The potential of Nuclear Medicine Imaging in RT

- **Detection** – Possibly better and earlier detection
  - Current imaging of disease is based on anatomic or physiologic changes that are a late manifestation of molecular changes that underlie the disease
- **Staging** - Improved staging and patient selection
  - Improved staging can define a more appropriate course of therapy



*Grigsby et al,  
JCO, 2001*

# Lymph Node Status

n = 256




Fig 1. Kaplan-Meier progression-free survival estimates based on pelvic lymph node status ( $P = .001$ ) ( $n = 101$ ).






Fig 2. Kaplan-Meier progression-free survival estimates based on para-aortic lymph node status ( $P = .0001$ ) ( $n = 101$ ).

# The potential of imaging in RT

- Target definition

- Improved target identification can significantly alter current treatment volumes
- The true extent of the disease may extend beyond anatomically defined volumes
- Anatomically defined volumes may contain regions of increased importance - Biological target volume (BTV)




Ling *et al* IJROBP 47:551-560, (2000)

Cu(II)-diacetyl-bis (N<sup>4</sup>-methylthiosemicarbazone) (<sup>60</sup>Cu-ATSM) PET - used to detect regions of tumor hypoxia

# The potential of multimodality-imaging in RT



- Target definition – Biological target volume



# The potential of multimodality-imaging in RT

- Dose distribution

- Treatment plans can be designed to deliver escalated doses to BTV
- With IMRT the concept of “dose painting” can be implemented
- The question becomes how much paint should be used



**Cu(II)-diacetyl-bis (N<sup>4</sup>-methylthiosemicarbazone) (<sup>60</sup>Cu-ATSM)**  
**PET - used to detect regions of tumor hypoxia**

# Altered/Escalated Dose Distributions

## <sup>60</sup>Cu-ATSM (Hypoxia) - Guided IMRT



- 80 Gy in 35 fractions to the hypoxic tumor sub-volume as judged by Cu-ATSM PET (red)
- GTV (blue) simultaneously receives 70 Gy in 35 fractions
- Clinical target volume (yellow)
- receives 60 Gy
- More than half of the parotid glands (green) are spared to less than 30 Gy.



# $^{60}\text{Cu}$ -ATSM-PET

Normoxic

Hypoxic





**Cervical Cancer**

*Dehdashti et al, IJROBP 55:1233-1238, (2003)*

$^{60}\text{Cu}$ -ATSM-PET

FDG-PET

Pre-therapy





$T/M = 2.3$

$^{60}\text{Cu}$ -ATSM-PET

FDG-PET

Pre-therapy




$T/M = 5.1$

# Results


- 6/15 pt's tumors were characterized as hypoxic
- All pts with hypoxic tumors developed recurrent disease (p=0.0005)
- 8/9 pts disease free (follow-up 6.1-13.9 months)
- All 6/6 pts with hypoxia had pelvic LN vs. 3/9 without hypoxic tumors (p =0.03)

## ATSM T/M ratio >3.5




**p = 0.0078**



# PET imaging for RT




**C-11 acetate**



**F-18 FDG**



**Prostascint**



**CT**

# The potential of multimodality-imaging in RT

- Treatment planning- continued

- Tumor biology (phenotype) and therapy selection –
  - » Intermodality and intramodality changes
  - » Radiation or chemotherapy sensitivity
  - » Incorporate biological response models to maximize the therapeutic ratio
  - » Indicator for more aggressive therapy in certain patients
- New treatment techniques
  - » Revised target volumes and desired dose distributions will require reevaluation of current treatment techniques

# FDG-PET Guided IMRT Dose escalation to PALN

- Rationale


- The survival of cervical cancer patients with para-aortic lymph node (PALN) metastasis is poor
- Results of RTOG-7920 suggest 45 Gy para-aortic lymph node irradiation (PALNI) is associated with better survival - *Rotman et al JAMA 274:387-393 (1995)*
- PALN dose is limited by bladder, rectum, colon, kidney, small intestine, and spinal cord radiation tolerances

- Objective

- Dose escalation to PALN while maintaining or even reducing dose to the surrounding critical organs using IMRT
- Use of PET to delineate target volume



# Process

- PET and CT scans are acquired in treatment position with PET/CT scanner
- Positive PALN are identified on PET and contours are related to CT
- Treatment plans are created to escalate dose to positive PALN




# Dose Distribution

First protocol patient - treatment start date 11-3-2003



50 Gy to PALN  
bed

60 Gy to  
positive PALN




# Altered/Escalated Dose Distributions

## PET Guided GYN Brachytherapy Implants

- Tandem and colpostat applicator inserted in the OR
  - Applicator design and mode of delivery (HDR or LDR) not important
- Foley catheter placed in the urinary bladder
- Patient taken to the PET scanner where 555 MBq (15 mCi)  $^{18}\text{F}$ -FDG ( $^{18}\text{F}$ -fluorodeoxyglucose) is intravenously administered
- Three small tubes containing  $^{18}\text{F}$ -FDG inserted into the applicator
- Whole pelvis scan obtained and images transferred to the treatment planning system (XiO, CMS, St. Louis, MO)
- 3D treatment plan created with target and normal structure DVHs

# Anatomy

## PET Guided GYN Brachytherapy Implants




# Treatment planning

## PET Guided GYN Brachytherapy Implants




- Applicators, critical structures and tumor contoured
- Software places sources at predefined positions with respect to applicator tips
- Source strengths and treatments times optimized
- Alternatively, deliver conventional dose distributions

### Tilted Coronal View




# Conventional Dose Distributions

## PET Guided GYN Brachytherapy Implants



# Optimized Dose Distributions PET Guided GYN Brachytherapy Implants




- Same Integrated Reference Air Kerma (IRAK) strength used for both plans
- Dwell positions rearranged to conform dose distribution

# The potential of multimodality-imaging in RT

- **Normal Tissue Sparing**
  - Functional properties of normal structures are used for guidance in organ organ sparing
  - Highly functioning portions of critical structures are given priority
  - Potentially can simplify delivery and improve tumor dose distribution

# SPECT Guided Bone Marrow Sparing

Tc-99m  
sulfur  
colloid




Roeske et al, *Radiotherapy and Oncology* 77 (2005) 11-17.

# SPECT Guided Bone Marrow Sparing


Blue lines  
identify active  
bone marrow



# PET, SPECT and CT Imaging during Radiation Treatment Planning



FDG PET grayscale




MAA SPECT grayscale

*Courtesy: MT Munley, MUSC*


# Dose-Function Histogram (DFH)

- Similar to the dose-volume histogram (DVH), but displaying the percent relative function of a structure versus dose.
- Uses the value of each voxel element:
  - Targets: F-18 FDG PET (metabolism)  
F-18 Misonidazole PET (hypoxia)
  - Normal: Tc-99m MAA SPECT (lung perfusion)

# Beam Orientation as a Function of Lung Function




# Comparison of Beam Orientations using the DVH



# Comparison of Beam Orientations using the DFH

Percent  
Perfusion  
(function)



# The potential of PET-imaging in RT


- **Evaluation** - Therapy response and follow-up
  - Tumor control
    - » Image at a molecular level
    - » Evaluate response shortly after initiation of therapy
    - » Possibly modify the planned course of therapy based on the initial response
  - Normal tissue function

# FDG-PET



IIb Cx Only—Pre & Post RT





# Follow-up FDG-PET Overall Survival





**Pre  
Treatment**






**First  
Implant**






**Third  
Implant**






**Third  
Implant**




**Fifth  
Implant**



**Post  
Treatment**





# $^{11}\text{C}$ -methionine PET measuring regional salivary gland function



Right-mean dose 30Gy

Left-mean dose 57 Gy


# 11C-methionine PET measuring regional salivary gland function



- a) Volume of distribution of 11C-methionine
- b)  $K$ , the net metabolic clearance of 11C-methionine


*Buus et al, Radiotherapy and Oncology 73:289-296, (2004).*

# 11C-methionine PET measuring regional salivary gland function



*Buus et al,  
Radiotherapy and  
Oncology 73:289-  
296, (2004).*

# RT Treatment Planning with PET/SPECT





- Setup reproducibility the primary concern
- Poor setup reproducibility may require deformable image registration

These can be separate units or a combined CT/PET or CT/SPECT machine


# Fusion/Image Registration

- Lack of anatomical definition makes a registration with CT image a necessity
- Due to the same lack of anatomical definition, CT and PET or SPECT study registration is somewhat challenging
- Combined scanners can simplify the process




# Multimodality Image Registration

- Registration Techniques:
  - Surface-based Registration
    - » Internal
    - » External
  - Image-based Registration
  - Point-based Registration
  - Automatic and semiautomatic computer assisted methods



# Patient positioning and immobilization





**Flat Tabletop**



**Immobilization Device**


# Fiducial Markers

- 0.5 cm diameter, 3.5 cm long, 0.25 ml, plastic, disposable microcentrifuge tubes
- VWRbrand Disposable Microcentrifuge Tubes, VWR Scientific Products, West Chester, PA
- CT, MR, and PET compatible
  - CT - Aluminum
  - MR - 4 mM  $\text{CuNO}_3$
  - PET -  $^{18}\text{F}$ -deoxyglucose
  - SPECT - 1  $\mu\text{Ci}$  of Tc-99M SC




# Fiducial Markers

- CT/PET compatible metallic copper markers
- Cu-64




# Fiducial Markers

- For face mask patients, markers are attached to the mask
- For body mould patients, markers are attached to the skin




# Fiducial Markers



# PET/CT scanner combined unit

- Multislice CT scanner mated to a PET scanner
- Possibly three scans acquired during procedure
  - Attenuation correction CT
  - PET
  - Treatment planning CT, with contrast if necessary



# PET/CT Scanner




# SPECT/CT Scanner




# PET/CT scanner combined unit

## Patient Motion





# Patient Motion



# RT Treatment Planning with PET

## TARGET DEFINITION



- Depending on image window and level setting, target volume can easily change by 50%
- SUV not a part of DICOM data
- SUV utility unclear

# Conclusions

- **The role of nuclear medicine imaging in radiation therapy and its impact needs further evaluation**
- **For several treatment sites it has already been shown that PET studies have a strong potential to improve staging, outcome prognosis, therapy selection, treatment planning, and follow-up**
- **Understanding PET and SPECT limitations is imperative for implementation in the treatment planning process**
- **The combined PET/CT and SPECT/CT scanner will simplify the treatment planning process**